

## Supplementary Information

### SERS nanostructures with engineered active peptides against an immune checkpoint protein

M. Gobbo,<sup>a</sup> I. Caligiuri,<sup>b</sup> M. Giannetti,<sup>c</sup> L. Lucio,<sup>a</sup> C. Mazzuca,<sup>c</sup> F. Rizzolio,<sup>b,d</sup> A. Palleschi,<sup>b</sup> M. Meneghetti<sup>a,\*</sup>

<sup>a</sup>Department of Chemical Sciences, University of Padova, via F. Marzolo 1, 35131 Padova, Italy.

<sup>b</sup>Pathology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, via F. Gallini 2, 33081 Aviano (PN), Italy

<sup>c</sup>Department of Chemical Science and Technologies, University of Rome "Tor Vergata", and CSGI unit of Rome, Via della Ricerca Scientifica, 00133 Rome, Italy

<sup>d</sup>Department of Molecular Sciences and Nanosystems, Ca' Foscari University of Venice, via Torino 155, 30172 Venice, Italy

\*Corresponding author. E-mail: [moreno.meneghetti@unipd.it](mailto:moreno.meneghetti@unipd.it)

Table S1 – Peptides characterization

Ligand	Sequence	HPLC $t_R$ [min]	ESI-MS Expect.	$[M+H]^+$ Found
L1	Ac-Cys-O <sub>2</sub> oc-O <sub>2</sub> oc-Trp-His-Arg-Ser-Tyr-Tyr-Thr-Trp-Asn-Leu-Asn-Thr-NH <sub>2</sub>	20.3 <sup>a</sup>	2074.9	2074.8
L2	Ac-Trp-His-Arg-Ser-Tyr-Tyr-Thr-Trp-Asn-Leu-Asn-Thr-O <sub>2</sub> oc-O <sub>2</sub> oc-Cys-NH <sub>2</sub>	20.6 <sup>a</sup>	2074.9	2074.8
P3	Lys-Lys-Lys-Gly-Gly-Trp-His-Arg-Ser-Tyr-Tyr-Thr-Trp-Asn-Leu-Asn-Thr-NH <sub>2</sub>	17.2 <sup>a</sup>	2138.1	2138.9
P4	Lys-Lys-Lys-Gly-Gly-Thr-Arg-Trp-Ser-His-Tyr-Asn-Thr-Leu-Trp-Tyr-Asn-NH <sub>2</sub>	17.8 <sup>a</sup>	2138.1	2138.2
L3	HS-PEG-Lys-Lys-Lys-Gly-Gly-Trp-His-Arg-Ser-Tyr-Tyr-Thr-Trp-Asn-Leu-Asn-Thr-NH <sub>2</sub>	19.3 <sup>b</sup>	> 5000	- <sup>c</sup>
L4	HS-PEG-Lys-Lys-Lys-Gly-Gly-Thr-Arg-Trp-Ser-His-Tyr-Asn-Thr-Leu-Trp-Tyr-Asn-NH <sub>2</sub>	18.9 <sup>b</sup>	> 5000	- <sup>c</sup>

<sup>a</sup> Elution conditions: 5-50% B in 30 min.

<sup>b</sup> Elution conditions: 20-60% B in 30 min; broad peaks centered at the  $t_R$

<sup>c</sup> See Figure S1 and Figure S2.




Figure S1. ESI(+)-Mass spectrum of the ligand 3. **A:** Full spectrum; **B:** Zoom of the region corresponding to  $[M+8H]^{8+}$  ions




Figure S2. ESI(+)-Mass spectrum of L4. **A:** Full spectrum; **B:** Zoom of the region corresponding to  $[M+3H]^{3+}$  ions.




Figure S3. A) Far UV CD and B) FTIR spectra of CLP002 (blue line) and *s*CLP002 (red line) in water. The molar ellipticity refers to the concentration of amino acid residues.




Figure S4. PD-L1 protein residues stabilizing the PD-1/PDL-1 complex. Residues belonging to the hydrophobic core<sup>1</sup> are in green.




Figure S5. Structures of PD-L1 (light blue)/ CLP002 (red) adduct for the three replicas of the MD simulations. Green spheres are relative to the hydrophobic region of the protein.

#### References

1. K. M. Zak, R. Kitel, S. Przetocka, P. Golik, K. Guzik, B. Musielak, A. Domling, G. Dubin and T. A. Holak, *Structure*, 2015, **23**, 2341-2348.